Cholangiocarcinoma Foundation

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott et al. · Journal of the National Comprehensive Cancer Network · 2021 · 999 citations · Full text

Surgical Oncology, Cancer Management, Pathology +22

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 196 citations · Full text

Overall Survival, Gastrointestinal Oncology, Medicine +7

NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023

Al B. Benson, Michael I. D’Angelica, Thomas A. Abrams et al. · Journal of the National Comprehensive Cancer Network · 2023 · 184 citations · Full text

Nccn Guidelines® Insights, Molecular Testing, Surgical Oncology +22

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · The Lancet Oncology · 2024 · 115 citations

Patient-reported Outcomes, Gastrointestinal Oncology, Medicine +7

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

Nathan A. Pennell, Melissa S. Dillmon, Laura A. Levit et al. · Journal of Clinical Oncology · 2020 · 84 citations · Full text

Nursing, Cancer Care Delivery, Health Policy +14